Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment

Journal of Clinical Psychiatry

Volumn 63, Issue 4, 2002, Pages 345-348

  Borovicka, Mary C ^a   Fuller, Matthew A ^a   Eric Konicki, P ^a   White, John C ^a   Steele, Vickie M ^a   Jaskiw, George E ^a  

^a Pharmacy Service 119(B)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; PHENYLPROPANOLAMINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OBESITY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0036232642     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0412     Document Type: Article

References (29)

1. Too many chronic mentally ill disabled patients are too fat
2. Weight gain with clozapine treatment
3. Differential effect of clozapine on weight: A controlled study
4. Clozapine-induced weight gain: Prevalence and clinical relevance
5. Clozapine and weight gain
6. Weight gain among schizophrenic patients treated with clozapine
7. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients
8. Olanzapine-induced weight gain
9. Antipsychotic-induced weight gain: A review of the literature
10. Report on the NIH Workshop on Pharmacologic Treatment of Obesity
11. Phenylpropanolamine and the risk of hemorrhagic stroke
12. Double-blind clinical evaluation of the anorectic activity of phenylpropanolamine hydrochloride drops and placebo drops in the treatment of exogenous obesity
13. A double-blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo
14. Phenylpropanolamine OROS (Acutrim) vs placebo in combination with caloric restriction and physician-managed behavior modification
15. Three controlled trials of weight loss with phenylpropanolamine
16. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
17. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
18. A rating scale for extrapyramidal side effects
19. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
20. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity
21. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients
22. Adverse effects of fenfluramine in treatment refractory schizophrenia
23. Manic psychosis after coffee and phenylpropanolamine
24. Phenylpropanolamine-induced psychosis: Potential predisposing factors
25. Adverse drug effects attributed to phenylpropanolamine: A review of 142 case reports
26. Manic psychosis associated with appetite suppressant medication, phenylpropanolamine
27. Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation